Related Experiment Video
Updated: Mar 31, 2026

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
Direct-to-consumer genetic testing: Perspectives on its value in healthcare
1Coriell Institute for Medical Research, Camden, New Jersey, USA.
Abstract:
The direct-to-consumer genetic testing debate reached a fever pitch in November 2013 when the US Food and Drug Administration (FDA) instructed 23andMe to discontinue marketing and sale of their Personal Genome Service. In 2015, 23andMe emerged with FDA approval to market a carrier test for Bloom syndrome only, and plans to release additional reports. The dust has settled and it is time to ask: What have we learned, and where do we go from here?
More Related Videos
Related Concept Videos
Issues And Trends In Healthcare Delivery System
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetics and Pharmacogenomics: Overview
Human Genetics
The complex relationship between genetics and psychology is observable through common biological components such...
What is Genetic Engineering?
Sensitivity, Specificity, and Predicted Value
Sensitivity is the...

